Waypoint Bio Raises $20 Million in Series A Funding to Advance Cell Therapy Programs

Waypoint Bio, a biotechnology company focused on developing cell therapies for solid tumors, has raised $20 million in a Series A funding round.

The financing was led by Amplify Partners. Existing and new investors, including General Catalyst, Time BioVentures, Mitsui Global Investments, Lux Capital, and Hummingbird Ventures, also participated in the round.

As part of the investment, Elliot Hershberg has joined the company's board of directors.

Funding to Support Clinical Development

Waypoint Bio plans to use the newly raised capital to advance its lead therapeutic candidate, WAY-103, into clinical trials. The company will also continue the development of WAY-200, a program targeting colorectal cancer, and strengthen its computational infrastructure for spatial biology research.

Building AI-Driven Cell Therapy Solutions

Founded by Xinchen Wang and Dr. Patrick Kaifosh, Waypoint Bio develops technology aimed at improving the design of CAR T cell therapies for solid tumors.

The company's platform combines machine learning, computer vision, and spatial screening technologies to analyze tumor environments and identify potential therapeutic targets. Through this approach, Waypoint Bio seeks to develop more precise cell therapies while reducing unwanted side effects.

Expanding Research Capabilities

According to the company, its lead program has shown higher therapeutic activity in preclinical animal studies when compared with several existing clinical benchmarks. The platform is designed to help researchers better understand tumor biology and accelerate the development of next-generation cancer treatments.

Waypoint Bio's leadership team includes Co-founder and Chief Executive Officer Xinchen Wang and Chief Technology Officer Dr. Patrick Kaifosh.